Trial intelligence / Profile preview

Octreotide in Pancreaticoduodenectomy

NCT02474914Completed

Sponsor
Mansoura University
Start
May 2014
Primary completion
Apr 2017
Modality
Peptides
Countries
1
01

Overview

Randomised, double-blind trial in pancreatic fistula (POPF) comparing Octreotide with Placebo (2 arms). Primary endpoint: Rate of development of postoperative pancreatic fistula at 30 days. Started May 2014; status: completed.

02

Drugs

octreotide
03

Conditions

pancreatic fistula (POPF)

Beyond the preview

Go deeper on NCT02474914.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02474914.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call